Center-Authored Papers

Filters: Author is Storer, Barry E  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Y
Yu J, Storer BE, Kushekhar K, Abu Zaid M, Zhang Q, Gafken PR, Ogata Y, Martin PJ, Flowers ME, Hansen JA et al..  2016.  Biomarker Panel for Chronic Graft-Versus-Host Disease.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 34(22):2583-2590. Abstract
W
Woo J, Howard NP, Storer BE, Fang M, Yeung CC, Scott BL, Deeg HJ.  2017.  Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.. Haematologica. 102(6):e216-e218.
Williams KM, Cheng G-S, Pusic I, Jagasia M, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S et al..  2016.  Fluticasone, Azithromycin, and Montelukast Treatment for New-Onset Bronchiolitis Obliterans Syndrome after Hematopoietic Cell Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 22(4):710-716. Abstract
Warren EH, Zhang XC, Li S, Fan W, Storer BE, Chien JW, Boeckh MJ, Zhao LP, Martin PJ, Hansen JA.  2012.  Effect of MHC and non-MHC donor/recipient genetic disparity on the outcome of allogeneic HCT.. Blood. 120(14):2796-2806. Abstract
Walter RB, Buckley SA, Pagel JM, Wood BL, Storer BE, Sandmaier BM, Fang M, Gyurkocza B, Delaney C, Radich JP et al..  2013.  Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission.. Blood. 122(10):1813-21. Abstract
Walter RB, Sandmaier BM, Storer BE, Godwin CD, Buckley SA, Pagel JM, Sorror ML, Deeg HJ, Storb R, Appelbaum FR.  2015.  Number of courses of induction therapy independently predicts outcome after allogeneic transplantation for acute myeloid leukemia in first morphological remission.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(2):373-8. Abstract
V
Vigorito AC, Campregher PV, Storer BE, Carpenter PA, Moravec CK, Kiem H-P, Fero ML, Warren EH, Lee SJ, Appelbaum FR et al..  2009.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD.. Blood. 114(3):702-8. Abstract
Vaughn JE, Storer BE, Armand P, Raimondi R, Gibson C, Rambaldi A, Ciceri F, Oneto R, Bruno B, Martin PJ et al..  2015.  Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 21(8):1418-24. Abstract
Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN et al..  2015.  Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.. Cancer. 121(20):3709-3716. Abstract
T
Tseng L-H, Storer BE, Petersdorf EW, Lin M-T, Chien JW, Grogan BM, Malkki M, Chen P-J, Zhao LP, Martin PJ et al..  2009.  IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation.. Transplantation. 87(5):704-10. Abstract
S
Storer BE, Gooley TA, Jones MP.  2008.  Adjusted estimates for time-to-event endpoints.. Lifetime data analysis. 14(4):484-95. Abstract
Storer BE.  2009.  Statistical considerations in studies of late effects in HCT.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15(1 Suppl):25-8.
Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F et al..  2013.  Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 31(12):1530-8. Abstract
Storb R, Gyurkocza B, Storer BE, Maloney DG, Sorror ML, Mielcarek M, Martin PJ, Sandmaier BM.  2013.  Allogeneic Hematopoietic Cell Transplantation Following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects.. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 19(5):792-8. Abstract
Stetsenko GY, Malekirad J, Paulson KG, Iyer JG, Thibodeau RM, Nagase K, Schmidt M, Storer BE, Argenyi ZB, Nghiem P.  2013.  p63 expression in Merkel cell carcinoma predicts poorer survival yet may have limited clinical utility.. American journal of clinical pathology. 140(6):838-44. Abstract
Sorror ML, Storer BE, Maloney DG, Sandmaier BM, Martin PJ, Storb R.  2008.  Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia.. Blood. 111(1):446-52. Abstract
Sorror ML, Maris MB, Sandmaier BM, Storer BE, Stuart MJ, Hegenbart U, Agura E, Chauncey TR, Leis J, Pulsipher M et al..  2005.  Hematopoietic cell transplantation after nonmyeloablative conditioning for advanced chronic lymphocytic leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(16):3819-29. Abstract
Sorror ML, Storer BE, Sandmaier BM, Maris M, Shizuru J, Maziarz R, Agura E, Chauncey TR, Pulsipher MA, McSweeney PA et al..  2008.  Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(30):4912-20. Abstract
Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P et al..  2011.  Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies.. JAMA : the journal of the American Medical Association. 306(17):1874-83. Abstract
Sorror ML, Storer BE, Fathi AT, Gerds AT, Medeiros BC, Shami P, Brunner AM, Sekeres MA, Mukherjee S, Peña E et al..  2017.  Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of Mortality.. JAMA oncology. Abstract
Sorror ML, Storer BE, Sandmaier BM, Maloney DG, Chauncey TR, Langston A, Maziarz RT, Pulsipher M, McSweeney PA, Storb R.  2008.  Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation.. Cancer. 112(9):1992-2001. Abstract
Sorror ML, Sandmaier BM, Storer BE, Maris MB, Baron F, Maloney DG, Scott BL, Deeg HJ, Appelbaum FR, Storb R.  2007.  Comorbidity and disease status based risk stratification of outcomes among patients with acute myeloid leukemia or myelodysplasia receiving allogeneic hematopoietic cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 25(27):4246-54. Abstract
Sorror ML, Storb RF, Sandmaier BM, Maziarz RT, Pulsipher MA, Maris MB, Bhatia S, Ostronoff F, Deeg HJ, Syrjala KL et al..  2014.  Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(29):3249-56. Abstract
Scott BL, Ramakrishnan A, Storer BE, Becker PS, Petersdorf SH, Estey EH, Deeg HJ.  2010.  Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept.. British journal of haematology. 148(6):944-7. Abstract
Scott BL, Ramakrishnan A, Fosdal M, Storer BE, Becker P, Petersdorf SH, Deeg HJ.  2010.  Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study.. British journal of haematology. 149(5):706-10. Abstract